title: Pioneering biased ligand offers efficacy with reduced on-target toxicity.
authors.forename: Katie
authors.initials: K
authors.lastname: Kingwell
mesh_terms: D000701:Analgesics, Opioid / Q000494:pharmacology; D017322:Clinical Trials, Phase II as Topic; D055808:Drug Discovery; D064420:Drug-Related Side Effects and Adverse Reactions / Q000378:metabolism / Q000517:prevention & control; D006801:Humans; D008024:Ligands; D017450:Receptors, Opioid, mu / Q000502:physiology*; D015398:Signal Transduction; D013141:Spiro Compounds / Q000494:pharmacology*; D013876:Thiophenes / Q000494:pharmacology*
chemical_list: C586842:((3-methoxythiophen-2-yl)methyl)((2-(9-(pyridin-2-yl)-6-oxaspiro(4.5)decan-9-yl)ethyl))amine; D000701:Analgesics, Opioid; D008024:Ligands; D017450:Receptors, Opioid, mu; D013141:Spiro Compounds; D013876:Thiophenes